T-lymphocyte cell therapy

DRUG CLASS:

T-lymphocyte cell therapy

News alerts, weekly reports and conference planners

Related drugs:

‹

ACTR707 (0)

ADCV01 (0)

ITIL-168 (0)

MOG autologous T-lymphocyte cell therapy (0)

ACTR707 (0)

ADCV01 (0)

ITIL-168 (0)

MOG autologous T-lymphocyte cell therapy (0)

›

TM4SF1 expression	Solid Tumor	TM4SF1 expression	Solid Tumor	T-lymphocyte cell therapy Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy Sensitive : C2	T-lymphocyte cell therapy Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy Sensitive : C2
CRLF2 rearrangement	Acute Lymphocytic Leukemia	CRLF2 rearrangement	Acute Lymphocytic Leukemia	T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy + ruxolitinib Sensitive : C2	T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy + ruxolitinib Sensitive : C2
MSLN positive	Solid Tumor	MSLN positive	Solid Tumor	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
MYC translocation + BCL2 translocation	Non-Hodgkin’s Lymphoma	MYC translocation + BCL2 translocation	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
BCL6 translocation	Non-Hodgkin’s Lymphoma	BCL6 translocation	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
Chr del(17p)	Non-Hodgkin’s Lymphoma	Chr del(17p)	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TP53 mutation	Non-Hodgkin’s Lymphoma	TP53 mutation	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	BCR-ABL1 T315I	B Acute Lymphoblastic Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CD19 positive + Chr t(8;21)	Acute Myelogenous Leukemia	CD19 positive + Chr t(8;21)	Acute Myelogenous Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CXCL12 elevation	Hepatocellular Cancer	CXCL12 elevation	Hepatocellular Cancer	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
KDR elevation	Hepatocellular Cancer	KDR elevation	Hepatocellular Cancer	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
VEGFA elevation	Hepatocellular Cancer	VEGFA elevation	Hepatocellular Cancer	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TP53 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation	B Acute Lymphoblastic Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
PD-L1 expression	Diffuse Large B Cell Lymphoma	PD-L1 expression	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TNFRSF17 deletion	Multiple Myeloma	TNFRSF17 deletion	Multiple Myeloma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TP53 mutation	Lymphoma	TP53 mutation	Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CDKN2B deletion	Diffuse Large B Cell Lymphoma	CDKN2B deletion	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3
CDKN2A deletion	Diffuse Large B Cell Lymphoma	CDKN2A deletion	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3	T-lymphocyte cell therapy Resistant: C3 – Early Trials T-lymphocyte cell therapy Resistant : C3
TP53 mutation	Diffuse Large B Cell Lymphoma	TP53 mutation	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TMB-L	Mast Cell Leukemia	TMB-L	Mast Cell Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TMB-L	Diffuse Large B Cell Lymphoma	TMB-L	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
LDH-L	Mast Cell Leukemia	LDH-L	Mast Cell Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
LDH-L	Diffuse Large B Cell Lymphoma	LDH-L	Diffuse Large B Cell Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CLDN6 positive	Soft Tissue Sarcoma	CLDN6 positive	Soft Tissue Sarcoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CLDN6 positive	Ovarian Cancer	CLDN6 positive	Ovarian Cancer	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CRLF2 rearrangement	Acute Lymphocytic Leukemia	CRLF2 rearrangement	Acute Lymphocytic Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
TNFRSF8 positive	Non-Hodgkin’s Lymphoma	TNFRSF8 positive	Non-Hodgkin’s Lymphoma	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
ATM mutation	Small Lymphocytic Lymphoma	ATM mutation	Small Lymphocytic Lymphoma	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4
ATM mutation	Chronic Lymphocytic Leukemia	ATM mutation	Chronic Lymphocytic Leukemia	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4
CD19 positive	Small Lymphocytic Lymphoma	CD19 positive	Small Lymphocytic Lymphoma	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4	T-lymphocyte cell therapy Sensitive: C4 – Case Studies T-lymphocyte cell therapy Sensitive : C4

T-lymphocyte cell therapy

T-lymphocyte cell therapy

Associations(51)

Associations
(51)